-DOCSTART- -X- O
Despite -X- _ O
improvements -X- _ O
in -X- _ O
the -X- _ O
management -X- _ O
of -X- _ O
community-acquired -X- _ B-Patient
pneumonia -X- _ I-Patient
( -X- _ I-Patient
CAP -X- _ I-Patient
) -X- _ I-Patient
, -X- _ O
morbidity -X- _ O
and -X- _ O
mortality -X- _ O
are -X- _ O
still -X- _ O
high -X- _ O
, -X- _ O
especially -X- _ O
in -X- _ O
patients -X- _ O
with -X- _ O
more -X- _ O
severe -X- _ O
disease. -X- _ O
Early -X- _ O
and -X- _ O
appropriate -X- _ O
antibiotics -X- _ O
remain -X- _ O
the -X- _ O
cornerstone -X- _ O
in -X- _ O
the -X- _ O
treatment -X- _ O
of -X- _ O
CAP. -X- _ B-Patient
However -X- _ O
, -X- _ O
two -X- _ O
aspects -X- _ O
seem -X- _ O
to -X- _ O
contribute -X- _ O
to -X- _ O
a -X- _ O
worse -X- _ O
outcome -X- _ O
: -X- _ O
an -X- _ O
uncontrolled -X- _ O
inflammatory -X- _ O
reaction -X- _ O
and -X- _ O
an -X- _ O
inadequate -X- _ O
immune -X- _ O
response. -X- _ O
Adjuvant -X- _ O
treatments -X- _ O
, -X- _ O
such -X- _ O
as -X- _ O
corticosteroids -X- _ B-Intervention
and -X- _ I-Intervention
intravenous -X- _ I-Intervention
immunoglobulins -X- _ I-Intervention
, -X- _ O
have -X- _ O
been -X- _ O
proposed -X- _ O
to -X- _ O
counterbalance -X- _ O
these -X- _ O
effects. -X- _ O
The -X- _ O
use -X- _ B-Outcome
of -X- _ I-Outcome
corticosteroids -X- _ I-Outcome
in -X- _ I-Outcome
patients -X- _ I-Outcome
with -X- _ I-Outcome
severe -X- _ I-Outcome
CAP -X- _ I-Outcome
and -X- _ I-Outcome
a -X- _ I-Outcome
strong -X- _ I-Outcome
inflammatory -X- _ I-Outcome
reaction -X- _ I-Outcome
can -X- _ I-Outcome
reduce -X- _ I-Outcome
the -X- _ I-Outcome
time -X- _ I-Outcome
to -X- _ I-Outcome
clinical -X- _ I-Outcome
stability -X- _ I-Outcome
, -X- _ I-Outcome
the -X- _ I-Outcome
risk -X- _ I-Outcome
of -X- _ I-Outcome
treatment -X- _ I-Outcome
failure -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
the -X- _ I-Outcome
risk -X- _ I-Outcome
of -X- _ I-Outcome
progression -X- _ I-Outcome
to -X- _ I-Outcome
acute -X- _ I-Outcome
respiratory -X- _ I-Outcome
distress -X- _ I-Outcome
syndrome. -X- _ I-Outcome
The -X- _ I-Outcome
administration -X- _ I-Outcome
of -X- _ I-Outcome
intravenous -X- _ I-Outcome
immunoglobulins -X- _ I-Outcome
seems -X- _ I-Outcome
to -X- _ I-Outcome
reinforce -X- _ I-Outcome
the -X- _ I-Outcome
immune -X- _ I-Outcome
response -X- _ I-Outcome
to -X- _ I-Outcome
the -X- _ I-Outcome
infection -X- _ I-Outcome
in -X- _ I-Outcome
particular -X- _ I-Outcome
in -X- _ I-Outcome
patients -X- _ I-Outcome
with -X- _ I-Outcome
inadequate -X- _ I-Outcome
levels -X- _ I-Outcome
of -X- _ I-Outcome
antibodies -X- _ I-Outcome
and -X- _ I-Outcome
when -X- _ I-Outcome
an -X- _ I-Outcome
enriched -X- _ I-Outcome
IgM -X- _ I-Outcome
preparation -X- _ I-Outcome
has -X- _ I-Outcome
been -X- _ I-Outcome
used -X- _ I-Outcome
; -X- _ O
however -X- _ O
, -X- _ O
more -X- _ O
studies -X- _ O
are -X- _ O
needed -X- _ O
to -X- _ O
determinate -X- _ O
their -X- _ O
impact -X- _ O
on -X- _ O
outcome -X- _ O
and -X- _ O
to -X- _ O
define -X- _ O
the -X- _ O
population -X- _ O
that -X- _ O
will -X- _ O
receive -X- _ O
more -X- _ O
benefit -X- _ O
. -X- _ O

